Skip to search boxSkip to navigationSkip to main content

Role of tumor-associated gangliosides in cancer progression

  • S. Birklé
    ,
  • G. Zeng
    ,
  • L. Gao
    ,
  • R. K. Yu
    ,
  • J. Aubry(corresponding author)
*Corresponding author for this work
  • École nationale vétérinaire, agroalimentaire et de l'alimentation, Nantes-Atlantique
    ,
  • Medical College of Georgia
    ,
  • ,
  • Institut national de la santé et de la recherche médicale
Scholary Output:
Contribution to journal
Review article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Neuroectodermic tumors can mostly be characterized by the presence of tumor-associated glycosphingolipid antigens, such as gangliosides, defined by monoclonal antibodies. Recently, cumulative evidence indicates that gangliosides modify the biological effects of several trophic factors, in vitro and in vivo, as well as the mitogenic signaling cascade that these factors generate. The functional roles of gangliosides in tumor progression can be revisited: (i) ganglioside antigens on the cell surface, or shed from the cells, act as immunosuppressors, as typically observed for the suppression of cytotoxic T cells and dendritic cells, (ii) certain gangliosides, such as GD3 or GM2, promote tumor-associated angiogenesis, (iii) gangliosides strongly regulate cell adhesion/motility and thus initiate tumor metastasis, (iv) ganglioside antigens are directly connected with transducer molecules in microdomains to initiate adhesion coupled with signaling, and (v) ganglioside antigens and their- catabolites are modulators of signal transduction through interaction with tyrosine kinases associated with growth factor receptors or other protein kinases. Given the potential importance of these sialylated gangliosides and their modulating biological behavior in vivo, further studies on the role of gangliosides are warranted.

Publication Information

Output type

Scholary Output:
Contribution to journal
Review article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 455-463 (9 pages)

Journal (Volume, Issue Number)

Biochimie (Volume 85, Issue 3-4)

Publication milestones

  • Published - 2003

Publication status

Published - 2003

ISSN

0300-9084

Publication IDs

  • Scopus: 0038532523
  • PubMed: 12770784

Publication metrics

Metrics

Scopus
citations
SciVal
citations
181
SciVal
FWCI
1.38
SciVal
Author count
5
SciVal
Paper percentile
97
SciVal
Top percentile
5
Fractional count
1
Fractional count
0.20
Fractional count
4
Fractional count
0.80
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
94
Citation count
212

Funding Details

Work in the laboratory of the authors was supported by National Institute of Health grants NS 11853, American Cancer Society grant IRG-105, and US Public Health Service grant NS11853-24. SB was also supported by a fellowship from the Fondation pour la Recherche Médicale, the Ligue Contre le Cancer, and the Groupement des Entreprises Françaises dans la Lutte contre le Cancer.
FundersFunding numbers
NIH
-
ACS
IRG-105
NINDS
R01NS011853
USPHS
NS11853-24
FRM
-
Ligue Contre le Cancer
-
GEFLUC
-